Gold nanoparticles (AuNP) have been widely used for drug delivery and have recently been explored for applications in cancer immunotherapy. Although AuNPs are known to accumulate heavily in the spleen, the particle distribution within immune cells has not been thoroughly studied. Here, we characterize the cellular distribution of Cy5 labeled 50 nm AuNPs within the immune populations of the spleen from naïve and tumor bearing mice using flow cytometry. Surprisingly, approximately 30% of the detected AuNPs were taken up by B cells at 24 hours, with about 10% in granulocytes, 18% in dendritic cells, and 8% in T cells. In addition, 3% of the particles were detected within myeloid derived suppressor cells, an immune suppressive population that could be targeted for cancer immunotherapy. Furthermore, we observed that, over time, the particles traveled from the red pulp and marginal zone to the follicles of the spleen. Taking into consideration that the particle cellular distribution did not change at 1, 6 and 24 hours, it is highly suggestive that the immune populations carry the particles and migrate through the spleen instead of the particles migrating through the tissue by cell-cell transfer. Finally, we observed no difference in particle distribution between naïve and tumor bearing mice in the spleen and detected nanoparticles within 0.7% of dendritic cells of the tumor microenvironment. Overall, these results can help inform and influence future AuNP delivery design criteria including future applications for nanoparticle-mediated immunotherapy.
Gold nanoparticles (AuNPs) have been applied in a number of cancer treatment modalities including drug delivery, gene therapy, and photothermal ablation. [1] [2] [3] [4] AuNPs can be easily synthesized and can be modified with a variety of materials including drugs, [2] polymers, [5] targeting ligands, [6] and nucleic acids. [7] Recently, AuNPs have been used for cancer immunotherapy as delivery vehicles for cancer antigens and immune adjuvants. [8, 9] Gold nanoparticles are well suited for immune cell targeting, for they are naturally taken up by the immune system upon in vivo injection, and it has been shown that AuNP mediated delivery enhances the effect of tumor antigens [8, 10, 11] and immune adjuvants. [9, 12] Yet, despite numerous studies focused on the biodistribution of gold nanoparticles, very little has been done to understand the cellular level distribution of nanoparticles in vivo, particularly within cells of the immune system. Biodistribution studies have focused on gold accumulation at the organ level, demonstrating that AuNPs show the highest accumulation in the liver and spleen. [13] [14] [15] [16] Shah et al. observed that gold nanoparticles traversed from the red pulp to the white pulp of the spleen over time but did not identify the immune cells involved in particle uptake. [17] In the liver, Bartneck and colleagues observed 30 fold higher accumulation of gold nanorods in immature macrophages as opposed to Kupffer cells; given that immature macrophages can cause inflammatory liver injury, their finding emphasizes the importance of identifying immune cell subsets that take up nanoparticles. [18] Therefore, in this study, we sought to characterize the distribution of gold nanoparticles within the major immune populations of the spleen, which is both the largest immune organ and one of the sites of highest AuNP accumulation.
In the spleen, arteries enter the red pulp--a framework of collagen and reticular fibers containing fibroblasts, macrophages, and reticular cells--and branch into smaller arterioles. [19, 20] The blood progresses into the venous sinuses, and most of it passes through the white pulp, which consists of the periarteriolar lymphoid sheath (PALS), the marginal zone, and the follicles. The PALS, also known as the T-cell zone, surrounds the arterioles and is composed of T lymphocytes that interact with dendritic cells and migrating B cells. The follicles are mainly composed of B cells but also contain follicular dendritic cells and T cells. Finally, the marginal zone is an efficient area of blood borne particulate capture, where marginal zone macrophages, dendritic cells, and B cells can act as antigen presenting cells (APCs) and migrate into the follicles to interact with T cells. [19, 20] Characterizing the distribution of AuNPs within the spleen is valuable for understanding nanoparticle immune effects and for developing nanoparticle mediated immunotherapies. For instance, Yen and colleagues have shown that AuNPs in the 2 nm to 40 nm size range can induce macrophage expression of inflammatory genes for TNFα and IL-6 in vitro. [21] Sumbayev et al., in turn, show that AuNPs can suppress IL-1β dependent inflammatory responses in vitro and in vivo in a size dependent manner. [22] Finally, Tsai and colleagues have demonstrated that treatment with particles in the 4 to 45 nm range can inhibit macrophage toll like receptor 9 responses to CpG, with smaller particles having a stronger effect than larger particles. [23] AuNP mediated therapies have progressed into clinical trials, [24] and thus it is important to further understand AuNP interactions with the immune system. On the other hand, nanoparticle uptake by immune cells could be exploited in the development of immunotherapies, [25, 26] again illustrating the importance of characterizing such interactions. Here, we assessed the splenic distribution of gold nanoparticles in naïve and tumor bearing mice and showed that AuNPs distributed widely across splenic immune cells, including B cells, T cells, granulocytes, dendritic cells, myeloid derived suppressor cells, and macrophages.
Results and Discussion

Gold nanoparticle characterization
50 nm gold nanoparticles coated with polyethylene glycol (PEG) were chosen as a design representative of particles that would be typically used in cancer applications. The size, shape, and surface coating can be optimized to prolong nanoparticle circulation so that the nanoparticles can reach the target tumor site. [13, 14, 27] Hydrophilic methylated polyethylene glycol (mPEG) coating protects particles from opsonization and subsequent blood clearance, and Perrault and colleagues have shown that PEGylated particles with core sizes in the 20 to 50 nm range are optimal for increased blood half-life. [28] Additionally, it has been shown that 50 nm is the optimal size for mammalian cell uptake of AuNPs. [29] Finally, particles in this size range have been used in a number of applications including photothermal therapy, [30] siRNA delivery, [31] vaccine delivery, [11] and drug delivery. [32] Therefore, 50 nm gold colloid nanoparticles conjugated with Cy5-terminated PEG-SH (5,000 MW) were used for our studies. Conjugation of the PEG on the gold surface was confirmed by observing a shift in absorbance when compared to the absorbance of citrate stabilized 50 nm gold colloids (Supplementary Figure 1) . The spectrum and the red color of the solution also indicated that the particles did not aggregate. The hydrodynamic diameter and zeta potential of the Cy5-PEGylated particles were also comparable to that of normal mPEG coated AuNPs, thus indicating that incorporating Cy5 onto PEG-AuNPs did not alter the particle characteristics (Supplementary Table 1 ). The PEG coating increased the diameter of the particle by ~ 30 nm compared to the citrate stabilized AuNPs.
Particle injection does not alter splenic cell distribution
Naïve C57BL/6J mice were injected with approximately 1.5 × 10 11 particles in PBS, a dose in the range of previous studies. [33] [34] [35] [36] [37] Mice that did not receive particle injections were used as controls. (Table 1) . [38] [39] [40] The spleen is mainly composed of CD3 + T cells and B220 + B cells (Figure 1 significant differences in the percentages of each population when compared to untreated controls.
Particles travel from the red pulp to the white pulp of the spleen over time
Histological samples of the spleen were stained with hematoxolin and eosin, and the gold nanoparticles were visualized by dark field microscopy, while their location was correlated with bright field microscopy of the tissue ( Figure 2 ). Untreated spleens displayed only normal tissue scattering and none of the characteristic scattering from nanoparticles. At 1 hour post-injection, the particles appeared and localized mainly within the red pulp and marginal zone of the spleen (red circles) ( Figure 2B ). At 6 hours, the particles were still present in the marginal zone and red pulp, but they were also visible within the follicles (red arrows) ( Figure 2C ). Finally, at 24 hours, the particles were mainly located at the center of the follicles while remaining particles were still visible in the red pulp and marginal zone ( Figure 2D ). These observations indicated that most of the particles moved from the red pulp to the marginal zone and to the middle of the follicle, and were consistent with previous findings by Shah and colleagues. [17] To further ensure that the presence of Cy5 does not affect the distribution of the particles, this experiment was repeated with AuNPs coated with unlabeled mPEG (Supplementary Figure 3) . The particles showed the same pattern over time, with most of the particles appearing in the red pulp at 1 hour and progressing to the follicles by 24 hours. Therefore, the presence of Cy5 had negligible effect on the distribution.
Nanoparticle signal is widely distributed but mainly detected in B cells
To identify the Cy5 positive cells in mice that received nanoparticle injections, gates for Cy5 events were established in untreated mice. The percentage of marker + Cy5 + in the spleen (e.g., B220 + Cy5 + divided by all events) was compared between treated and untreated mice for the immune populations mentioned in Table 1 and at all time points (Supplementary Figure 2 ). All percentages were significantly different than control (p < 0.01), showing that the Cy5 + events were from the injected nanoparticles.
Next, we evaluated the distribution of Cy5 events within the immune cells, i.e. the percent of the nanoparticle dose that is in each immune population. For instance, the percent of dose detected within B220 + cells is given by B220 + Cy5 + events divided by all Cy5 + events. The distribution of the nanoparticle Cy5 dose in the respective populations at 1, 6, and 24 hours post-injection are shown in Figure 3 . At 1 hour, the highest percent of Cy5 events was found within B220 + B cells (32%), and this percentage is significantly higher than that found in CD3 + T cells (12%, p < 0.0001), CD11b + monocytes and macrophages (7.7%, p < 0. At 6 hours, 58.5% of the Cy5 signal was detected in B220 + cells, and the percentage within this population was significantly higher than that found in all other populations (p < 0.0276) ( Figure 3B ). The trend was similar at 24 hours with the highest percentages of Cy5 dose found within B220 + CD21 ++ CD23 − , CD21 + CD23 + , and CD11c + cells ( Figure 3C ). Interestingly, the percentage in B cells increased significantly from 1 hour to 6 hours, going from 32% to 58.5% (p = 0.0372) ( Figure 3D) . The percentage was then significantly decreased at 24 hours to 31.4% (p = 0.0415). In turn, the dose in Gr-1 + cells significantly decreased from 15.8% at 1 hour to 7.3% at 6 hours. The only other change over time was observed in CD21 + CD23 + cells, where the percentage dropped from 36.6% at 6 hours to 17.7% at 24 hours (p=0.0065). The cause of these changes was not evident and may be the result of fluorescence differences over time or experimental variability.
There were no other significant differences in Cy5 distribution within each population, and more importantly, the pattern of distribution remained the same across the different time points. The histology images showed that the particles traveled through the spleen over time, and given that the distribution pattern did not change in the 24 hour period, the particles were likely to have migrated with the cells instead of transferring from one cell population to another. The movement of the particles may result from cells such as marginal zone B cells and dendritic cells taking up nanoparticles and then migrating to the follicle. [20] Of course, mechanisms of cellular transfer such as trogocytosis [41] and exocytosis could also be at play, and these potential mechanisms merit further study. [38, 39] however, uptake by those subsets needs to be further explored in future studies.
Various biodistribution studies have shown that despite AuNP modifications aimed at avoiding spleen and liver uptake, such as PEG coating, targeting ligands, and size and charge variations, a substantial portion of the injected dose will inevitably be retained in the spleen. [13] Studies show a wide range of spleen accumulation, with reports varying between 10% to over 60% of the injected dose reaching the spleen. [27, 34, 43] The consequences of such accumulation are still unclear. A previous study in rats by Terentyuk and colleagues has shown that 50 nm PEGylated gold nanoparticles can cause blood congestion in the red pulp and damage to the white pulp. [44] Balasubramanian et al. studied AuNP effects on gene expression in rat spleens and reported down-regulation of genes associated with healing and other defense responses. [36] Furthermore, as aforementioned, there is ongoing study into the effects of AuNPs on inflammatory responses in vitro and in vivo. [21] [22] [23] In this study, the histology slides were reviewed by an independent pathologist, and the analysis showed that nanoparticle treatment caused no inflammation or signs of splenotoxicity such as apoptosis or atrophy. However, the particle treatment resulted in vascular congestion as well as red pulp expansion, indicated by an increased presence of histiocytes, lymphocytes, and megakaryocytes. The results presented here elucidate which splenic immune populations interact with nanoparticles after intravenous injection as well as how the spleen reacts to a typically used nanoparticle design and thus can be used to inform future studies on AuNP immune effects.
Percent of each immune population positive for Cy5 signal
Next, we examined the percentage of each cell population that was Cy5 positive (Figure 4) . At 1 hour post injection, approximately 2.9% of CD21 ++ CD23 − cells were positive for Cy5, significantly higher than the percentages within all other populations (p < 0.0086). This higher proportion as well as the localization of nanoparticles in the marginal zone ( Figure 2 ) again suggests that the particles are taken up by marginal zone B cells. The involvement of marginal zone B cells is likely, for this population in mice can uptake blood borne particulates that have been coated with opsonins. [40] AuNPs are known to be opsonized once entering the blood stream [13, 14] and may thus be recognized by marginal zone B cells in the spleen.
By 24 hours, about 2.5% of CD11c + dendritic cells, 3.1% of Gr-1 + granulocytes, and 1.4% of MDSCs were positive for Cy5. Interestingly, these percentages were comparable to the percentage of B220 + B cells positive for Cy5, even though the percentage of B cells in the spleen is significantly higher. There were no significant differences in the percentages of cells associated with Cy5 over time, again suggesting that the nanoparticles did not transfer from one cell population to another but instead remained within respective populations that migrate over time. Overall, the distribution of the nanoparticle dose and the percentage of each cell population involved indicate that nanoparticles primarily interact with B cells, T cells, granulocytes, and dendritic cells in the spleen. Importantly, a measureable percentage of the nanoparticle Cy5 signal is detected within MDSCs. Given the comparable percentage of cells positive for Cy5 between myeloid cells and B220 + B cells, the myeloid populations may be more efficient at capturing nanoparticles and could potentially be targets for nanoparticle mediated drug delivery.
Nanoparticle distribution is unaffected in a B16F10 melanoma model
To assess whether these distribution patterns would be the same in a disease model, we tested the nanoparticles in mice bearing a B16F10 melanoma tumor. C57BL/6J mice were implanted with subcutaneous B16F10 tumors and injected with the same dose of particles once the tumors reached approximately 1 cm 2 in size. The spleens were harvested after 24 hours and analyzed as before. The distribution of splenic populations showed a significant drop in CD3 + T cells when compared to non-tumor bearing mice (p=0.0324) ( Figure 5A ). Interestingly, there was no significant difference in either Cy5 events distribution or the percent of cells positive for Cy5 when compared to naïve mice examined 24 hours after nanoparticle injection ( Figures 5B and 5C ). Therefore, the nanoparticle distribution within major immune cells does not change in tumor bearing mice.
It is worth noting that approximately 22% of Cy5 events were found in CD11c + dendritic cells, with 15% in Gr-1 + granulocytes and 4.8% in CD11b + Gr-1 + MDSCs of tumor bearing mice. Importantly, the nanoparticles reach these populations by passive targeting, without the aid of ligands or antibodies specific for these cells. The involvement of these populations indicates that they could be potential targets for nanoparticle mediated immunotherapy. The particles' high association with dendritic cells makes them promising vehicles for delivery of immune antigens and adjuvants. [10, 25] In addition, Niikura and colleagues recently reported that 40 nm spherical AuNPs can act as adjuvants for vaccines, for they can induce antigen specific antibody production in vivo and bone marrow derived dendritic cell inflammatory responses in vitro. [11] The involvement of granulocytes and myeloid derived suppressor cells is also important because granulocytic and myeloid progenitor populations in the spleen have been shown to provide cancer sites with tumor associated macrophages and neutrophils that promote tumor growth. [45] In addition, it has been well established that MDSCs are recruited to the tumor microenvironment and suppress anti-tumor immune responses by inhibiting T cell activity and promoting antigen tolerance. [42, 46] Targeting MDSCs for immune modulation is a promising immune therapy approach that is a subject of ongoing work. [47, 48] Given the association of MDSCs with nanoparticle signal, this population could potentially be targeted with AuNP mediated delivery of drugs that have been shown to suppress MDSC activity, such as sunitinib [49] or CpG. [48, 50] We also assessed particle distribution in the immune cells of the tumor microenvironment, characterizing Cy5 events within CD8 + cytotoxic T cells, CD4 + helper T cells, CD11c + dendritic cells, CD11b + monocytes and macrophages, and CD11b + Gr-1 + MDSCs. To ensure that Cy5 events were accurately captured, the percent of Marker + Cy5 + cells in the entire tumor was calculated in untreated mice and in mice treated with AuNPs, as was done in the spleen. The percentage of CD11c + Cy5 + cells was significantly higher than in untreated controls (p=0.0376), indicating that the Cy5 events were due to the particle injection ( Figure  6 ). This difference was not significant in the other immune populations, and, as such, we could only detect the nanoparticle Cy5 signal within CD11c + dendritic cells. Approximately 1.8% of the tumor microenvironment was composed of CD11c + dendritic cells, and about 0.01% of all cells in the microenvironment were CD11c + Cy5 + . However, 36 +/− 10% of all Cy5 events detected were found within CD11c + cells, indicating that a large portion of the AuNP dose that reaches the tumor resides within dendritic cells. Additionally, 0.7 +/− 0.2% of CD11c + cells were positive for Cy5. We could not account for the remaining Cy5 signal, but the tumor microenvironment is a complex milieu of inflammatory cells, fibroblasts, blood vessels, and tumor cells, [51, 52] and the distribution of AuNPs within the various cell types merits further work. Overall, nanoparticles reach dendritic cells both in the spleen and the tumor, again illustrating their potential for targeting this population.
Conclusions
This study elucidates the immune cell distribution of 50 nm PEG coated gold nanoparticles in the spleen, showing that the nanoparticles associate with a range of immune populations. The signal from the particles is most highly present in B cells, granulocytes, dendritic cells, and T cells, and it appears that the signal remains associated with these populations in the 1 hour to 24 hour range examined in this study. The particles show high association with CD21 ++ CD23 − cells, indicating uptake by marginal zone B cells, but these observations need to be further explored. The anatomical location of the particles vary with time, with AuNPs mainly localizing to the red pulp and marginal zone at 1 hour and appearing in the marginal zone and follicle between 6 and 24 hours after injection. The consistent particle distribution over time observed using flow cytometry suggests that the particles may migrate with the immune cells as they traverse the spleen. It is possible that marginal zone B cells and dendritic cells take up particles and migrate into the follicle following uptake. Finally, the distribution patterns observed did not vary between tumor bearing and non-tumor bearing mice, and a detectable percentage of Cy5 signal was present in dendritic cells, granulocytes, and MDSCs of the spleens of tumor bearing mice. In addition, AuNPs can be detected in the dendritic cells of the tumor microenvironment. These populations and others could potentially be targeted for cancer immunotherapy, and the distribution characterized here could prove informative for future nanoparticle toxicity studies.
Experimental Section
Nanoparticle conjugation 50 nm citrate stabilized gold nanoparticles (Ted Pella) were conjugated with 5,000 MW polyethylene glycol terminated with Cy5 purchased from NanoCS, MA. Absorbance was measured using the Cary 60 UV-Vis (Agilent Technologies), hydrodynamic diameter was measured using a 90 Plus Particle Size Analyzer (Brookhaven), and the zeta potential was measured with a Zen 3600 Zetasizer (Malvern Instruments).
Animal studies and tumor model
C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) were kept in the Animal Resource Facility of Rice University, and the study was approved by the Institutional Animal Care and Use Committee. The particles were suspended in PBS and injected intravenously at a concentration of 1.5×10 11 particles per injection. After 1 (n=6), 6 (n=6), or 24 hours (n=5), the mice were euthanized, and the spleens were harvested by passing through a 70 µm cell strainer. The cell suspension underwent red blood cell lysis (Sigma) prior to staining with antibodies. The following antibodies were obtained from BD Biosciences and used for flow cytometry analysis: anti-CD11c PE, anti-B220 PE, anti-CD3 FITC, anti-CD11b PE, antiGr-1 FITC, anti-CD23 PE, and anti-CD21 FITC. The stained samples were then analyzed using a BD FACSCantoII flow cytometer.
For the tumor study, mice were injected subcutaneously with 5×10 5 B16-F10 melanoma cells in PBS (n=7). Once the tumors reached approximately 1 cm 2 in size, the mice received an intravenous injection of nanoparticles. Tumor bearing mice that did not receive particle injections were used as controls (n=4). The spleens were harvested after 24 hours and analyzed as previously described. The tumors were also harvested, passed through a cell strainer, and treated with red blood cell lysis buffer. The following antibodies were used for flow cytometry: anti-CD8 PE, anti-CD3 FITC, anti-CD11c PE, anti-CD11b PE, and anti-GR-1 FITC (BD Biosciences). The B16F10 cells were grown in Dulbecco's Modified Eagle Medium (DMEM), supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin/ streptomycin. The cells were kept at 37°C and 5% CO 2 . Percentage of immune populations in the spleens of mice that were untreated or harvested 1, 6 or 24 hours after AuNP intravenous injection. Percentage of CD11c positive and particle positive cells (CD11c + Cy5 + ) in the tumor microenvironment. *, p < 0.05. 
